Halozyme Therapeutics, Inc. (HALO) Given Consensus Recommendation of “Hold” by Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned an average rating of “Hold” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $20.33.

Several equities analysts have recently weighed in on HALO shares. Zacks Investment Research cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 11th. BidaskClub upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. Cantor Fitzgerald restated a “buy” rating and issued a $24.00 price objective on shares of Halozyme Therapeutics in a report on Monday, February 4th. JMP Securities reiterated a “buy” rating and issued a $21.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, February 27th. Finally, ValuEngine downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th.

Shares of NASDAQ HALO traded down $0.34 during mid-day trading on Friday, hitting $15.99. The company had a trading volume of 27,933 shares, compared to its average volume of 773,189. The stock has a market capitalization of $2.48 billion, a price-to-earnings ratio of -28.55 and a beta of 1.79. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.86 and a quick ratio of 2.71. Halozyme Therapeutics has a one year low of $13.24 and a one year high of $20.43.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. The company had revenue of $56.95 million during the quarter, compared to analysts’ expectations of $67.80 million. Halozyme Therapeutics had a negative return on equity of 31.86% and a negative net margin of 52.90%. Halozyme Therapeutics’s revenue for the quarter was up 84.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.19) EPS. On average, sell-side analysts expect that Halozyme Therapeutics will post -0.43 EPS for the current year.

A number of large investors have recently modified their holdings of HALO. JPMorgan Chase & Co. raised its holdings in shares of Halozyme Therapeutics by 12.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,601,604 shares of the biopharmaceutical company’s stock valued at $65,441,000 after buying an additional 400,008 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Halozyme Therapeutics by 24.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 802,171 shares of the biopharmaceutical company’s stock valued at $14,575,000 after buying an additional 158,349 shares during the period. Teachers Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 1.1% during the 3rd quarter. Teachers Advisors LLC now owns 322,091 shares of the biopharmaceutical company’s stock valued at $5,852,000 after buying an additional 3,638 shares during the period. TIAA CREF Investment Management LLC raised its holdings in shares of Halozyme Therapeutics by 2.6% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 538,680 shares of the biopharmaceutical company’s stock valued at $9,788,000 after buying an additional 13,651 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Halozyme Therapeutics by 28.1% during the 3rd quarter. Legal & General Group Plc now owns 54,981 shares of the biopharmaceutical company’s stock valued at $999,000 after buying an additional 12,044 shares during the period. Institutional investors and hedge funds own 83.33% of the company’s stock.

Halozyme Therapeutics Company Profile

There is no company description available for Halozyme Therapeutics Inc

Featured Article: Calculating net profit and net profit margin ratio

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.